Cutaneous Basal Cell Carcinoma
Research activity in cutaneous basal cell carcinoma is centered on neoadjuvant immunotherapy for high-risk, potentially resectable disease, with interest in combinations involving cemiplimab, imiquimod, and fractional laser therapy.
- Neoadjuvant immunotherapy
- Topical immune modulation
- Skin cancer surgery
The sponsor’s work in this area reflects a focus on non-melanoma skin cancer management and treatment strategies aimed at improving local disease control before surgery.
Lung Cancer
In lung cancer, the funded research includes treatment approaches for advanced disease with emphasis on maintenance immunotherapy and immune-based combinations in small cell lung cancer.
- Extensive-stage small cell lung cancer
- Maintenance immunotherapy
- Dendritic cell vaccination
These studies show an interest in thoracic oncology and in strategies that extend disease control after initial treatment.
Non-small cell lung cancer (NSCLC)
Research in non-small cell lung cancer focuses on patients with EGFR-mutant advanced or metastatic disease, with attention to targeted treatment combinations involving osimertinib and repotrectinib.
- EGFR-mutant NSCLC
- Targeted therapy combinations
- Advanced and metastatic disease
This area of interest highlights precision medicine approaches within lung oncology, particularly for molecularly defined tumors.
Immuno-oncology
Across its studies, the sponsor places strong emphasis on immuno-oncology, including checkpoint inhibition, immune-based maintenance strategies, and combinations designed to enhance antitumor activity in both solid tumors and skin cancer.
- Checkpoint inhibition
- Immune combination therapy
- Antitumor immune activation
The research portfolio links immune-based treatment development with oncology care in Barcelona and broader European clinical practice.
